SK bioscience and Sanofi have announced plans for global Phase III studies, which will assess the safety and immunogenicity ...

V116 (PCV21) was more cost-effective than PCV20 alone and PCV15 plus PPSV23 for the prevention of adult pneumococcal disease.

As of 9:17 a.m. on this day, SK bioscience is trading at 53,400 won, which is an increase of 3,900 won (7.88%) compared to ...

The Centers for Disease Control and Prevention (CDC) now recommends that American adults over the age of 50 receive the ...

All vaccines that are authorised by regulatory authorities come with important safety information that should be carefully ...

At the 116,865 pre-travel visits, 25% of travelers were eligible to receive the pneumococcal vaccine, but only 68% of the ...

Pneumococcal Vaccine market Forecast to Surge to US$ 14.43 Billion by 2032, Achieving a Remarkable 6.4% CAGR ...

Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...

Changes to both schedules include new and updated recommendations for COVID-19 vaccine, change to trivalent influenza vaccines ...

Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate ...

Pneumococcal Vaccination Recall Program for adults aged 70 years and older, a simple QI activity to enhance patient care through a free patient ...

While changes in cost varied by vaccine, the average overall inflation-adjusted private-sector costs climbed 0.9% and 1.4% ...